We have become bullish on shares of Green Organic Dutchman Holdings Ltd (OTCMKTS:TGODF) as of a couple weeks ago. The stock was dashed lower following Aurora’s listed sale of its position in the name in November. But we have seen some renewed support come back into the picture in recent action. The next target could be a test of the 50-day MA in the $2.30 area. To further flesh out the story, the company just announced it has appointed Dr. Caroline MacCallum and Jacques Dessureault to its Board of Directors.
According to the release, “Dr. Caroline MacCallum is one of the world’s most prominent experts in cannabinoid-based medicine. She is an internist, complex pain and cannabinoid clinician, researcher and clinical instructor in the Department of Medicine, an adjunct professor in the Faculty of Pharmaceutical Sciences Program and an associate member of the Department of Palliative Care at the University of British Columbia. She is also the medical director at Greenleaf Medical Clinic, where she has assessed and developed cannabinoid treatment plans for more than 3,000 patients across Canada.”
Green Organic Dutchman Holdings Ltd (OTCMKTS:TGODF) is a research & development company licensed under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) to cultivate medical cannabis.
The Company carries out its principal activities producing cannabis from its facilities in Ancaster, Ont., pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada) and its regulations.
The Company grows high quality, organic cannabis with sustainable, all-natural principles. TGOD’s products are laboratory tested to ensure patients have access to a standardized, safe and consistent product. TGOD has a funded capacity of 116,000 kg and is building 970,000 sq. ft. of cultivation facilities in Ontario and Quebec.
The Company has developed a strategic partnership with Aurora Cannabis Inc. (TSX:ACB) whereby Aurora has invested approximately C$78.1 million for an approximate 17.5% stake in TGOD. In addition, the Company has raised approximately C$290 million dollars and has over 5,000 shareholders. TGOD’s Common Shares and warrants issued under the indenture dated November 1, 2017 trade on the TSX under the symbol “TGOD” and “TGOD.WT”, respectively.
Find out when $TGODF reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
As noted above, TGODF just announced it has appointed Dr. Caroline MacCallum and Jacques Dessureault to its Board of Directors. In all, we’ve witnessed 8% added to share values of the stock over the past week of action. In addition, the listing has benefitted from a jump in recent trading volume to the tune of 21% above the average volume levels in play in this stock over the longer term.
“Dr. MacCallum’s vast experience in cannabinoid research will be invaluable to TGOD,” commented Brian Athaide, CEO & Director of TGOD.
“She has been recognized by her peers in the medical industry as an expert in medical cannabis with a focus on dosing, which will be critical as we prepare to launch a suite of multi-dose products under the recently announced Responsible Regulation of Edible Cannabis Products in Canada,” continued Athaide.
At this time, carrying a capital value in the market of $559.69M, TGODF has a significant war chest ($257.6M) of cash on the books, which compares with about $15.1M in total current liabilities. The company is pre-revenue at this point. As more color becomes clear on the name, we will review the situation and update our take. Sign-up for continuing coverage on shares of $TGODF stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $TGODF, either long or short, and we have not been compensated for this article.